Person: YEŞİLBURSA, DİLEK
Loading...
Email Address
Birth Date
Research Projects
Organizational Units
Job Title
Last Name
YEŞİLBURSA
First Name
DİLEK
Name
7 results
Search Results
Now showing 1 - 7 of 7
Publication Coronary risk factors and coronary angiography results of 12.201 patients(Elsevier, 2015-07-01) Günay, Şeyda; Serdar, Osman Akın; Özyılmaz, Sinem; Dereli, Seçkin; Aydınlar, Ali; Baran, İbrahim; Özdemir, Burhan; Yeşilbursa, Dilek; Güllülü, Sumeyye; Kaderli, Aysel Aydın; Şentürk, Tunay; GÜNAY POLATKAN, ŞEYDA; SERDAR, OSMAN AKIN; Özyılmaz, Sinem; Dereli, Seçkin; AYDINLAR, ALİ; Baran, İbrahim; Özdemir, Burhan; YEŞİLBURSA, DİLEK; GÜLLÜLÜ, NAZMİYE SÜMEYYE; Kaderli, Aysel Aydın; ŞENTÜRK, TUNAY; Uludağ Üniversitesi; 0000-0003-1744-8883; 0000-0003-0090-3835; 0000-0002-8974-8837; 0000-0003-4829-8400; 0000-0003-0012-345X; AAI-5350-2021; AAI-6632-2021; AAG-8709-2020; AAB-5861-2021; AAJ-3962-2020; C-1517-2017; AAF-5116-2019; CDA-1396-2022; FRF-3343-2022Publication Acute effect of hemodialysis on arterial elasticity(TÜBİTAK, 2015-01-01) Sağ, Saim; Yeşilbursa, Dilek; Yıldız, Abdülmecit; Dilek, Kamil; Şentürk, Tunay; Serdar, Osman Akın; Aydınlar, Ali; Sağ, Saim; YEŞİLBURSA, DİLEK; YILDIZ, ABDULMECİT; DİLEK, KAMİL; ŞENTÜRK, TUNAY; SERDAR, OSMAN AKIN; AYDINLAR, ALİ; Uludağ Üniversitesi/Tıp Fakültesi/Kardiyoloji Anabilim Dalı.; Uludağ Üniversitesi/Tıp Fakültesi/Nefroloji Anabilim Dalı.; 0000-0003-1744-8883; 0000-0001-8404-8252; AAW-9185-2020; C-1517-2017; AAF-5116-2019; AAI-6632-2021; EHA-0046-2022; HIG-9032-2022; EUF-5229-2022Background/aim: Reduced arterial elasticity is an independent predictor of cardiovascular mortality in patients with end-stage renal disease (ESRD). Hemodialysis (HD) treatment per se can bring additional risk factors for vascular disease. Our study was designed to determine whether a single hemodialysis session leads to an acute alteration in parameters of arterial elasticity in ESRD.Materials and methods: In this study, 58 patients undergoing chronic hemodialysis and 29 healthy controls were enrolled. Large artery elasticity index (LAEI) and the small artery elasticity index (SAEI) were measured by applanation tonometry. The acute effect of a hemodialysis session on arterial elasticity indices was assessed by comparison of prehemodialysis and posthemodialysis determinations.Results: At baseline, LAEI did not differ significantly in patients compared with controls. In contrast, the SAEI was significantly lower in patients (4.1 +/- 2.6 mL/mmHg x 100) than in healthy individuals (8.9 +/- 3.4 mL/mmHg x 100, P < 0.05). In patients with ESRD, no significant changes in LAEI was observed after HD, but SAEI deteriorated significantly (from 4.1 +/- 2.6 mL/mmHg x 100 to 3.4 +/- 2.3, P < 0.05).Conclusion: We conclude that ESRD patients face a significant reduction in SAEI, which is exacerbated by a dialysis procedure.Publication Coronary risk factors and coronary angiography results of 12.257 patients(Elsevier, 2013-10-29) Günay, Şeyda; Serdar, Osman Akın; Özyılmaz, Sinem Özbay; Dereli, Seçkin; Aydınlar, Ali; Baran, İbrahim; Özdemir, Bülent; Yeşilbursa, Dilek; Güllülü, Sümeyye; GÜNAY POLATKAN, ŞEYDA; SERDAR, OSMAN AKIN; Özyılmaz, Sinem Özbay; Dereli, Seçkin; AYDINLAR, ALİ; Baran, İbrahim; ÖZDEMİR, BÜLENT; YEŞİLBURSA, DİLEK; GÜLLÜLÜ, NAZMİYE SÜMEYYE; Uludağ Üniversitesi/Tıp Fakültesi/Kardiyoloji Anabilim Dalı; 0000-0003-1744-8883; 0000-0002-7788-9739; 0000-0003-0090-3835; AAF-5116-2019; AAG-8709-2020; AAI-5350-2021; AAI-6632-2021; AAJ-3962-2020; AAB-5861-2021; CDA-1396-2022; JHE-3353-2023; EHA-0046-2022; JGR-6552-2023Publication Serum cancer from lung-6: Promising biomarker to differentiate cpfe from ipf(Mattioli 1885, 2022-01-01) Uzaslan, Esra; DEMİRDÖĞEN, EZGİ; UZASLAN, AYŞE ESRA; GÖREK DİLEKTAŞLI, ASLI; ÖZKAYA, GÜVEN; Dilektaşlı, Aslı Görek; Öztürk, Nilüfer Aylin Acet; Karadağ, Mehmet; KARADAĞ, MEHMET; ACET ÖZTÜRK, NİLÜFER AYLİN; YEŞİLBURSA, DİLEK; Yeşilbursa, Dilek; Budak, Ferah; BUDAK, FERAH; Öztürk, Alper; Ursavaş, Ahmet; COŞKUN, NECMİYE FUNDA; URSAVAŞ, AHMET; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Kardiyoloji Anabilim Dalı.; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Biyoistatistik Anabilim Dalı.; Bursa Uludağ Üniversitesi/Tıp Fakültesi/İmmunoloji Anabilim Dalı.; 0000-0002-7400-9089; 0000-0001-7099-9647; 0000-0002-6375-1472; 0000-0001-7625-9148; 0000-0003-3604-8826; 0000-0003-0297-846X; 0000-0002-9027-1132; AAD-1271-2019; JPK-7012-2023; IZP-9398-2023; A-4421-2016; F-4657-2014; AAI-3169-2021; AAG-8744-2021Background: Combined pulmonary fibrosis and emphysema (CPFE) has been recognised as a phe-notype of pulmonary fibrosis. We aimed to compare serum surfactant protein-A (SP-A), surfactant protein-D (SP-D) and Krebs von den Lungen-6 (KL-6) levels, functional parameters, in CPFE and IPF (idiopathic pul-monary fibrosis) patients. Methods: Patients diagnosed with ???CPFE??? and ???IPF??? were consecutively included in 6 months as two groups. The patients with connective tissue diseases are excluded. Results: In this study, 47 patients (41 males, 6 females) with CPFE (n = 21) and IPF (n = 26) with a mean age of 70.12 ?? 8.75 were evaluated. CPFE patients were older, had more intense smoking history, had lower DLCO/VA, lower FVC, and worse six-minute walking distance than the IPF group (p=0.005, p=0.027, p=0.02, p<0.001, p=0.001, respec-tively). Serum KL-6 levels were higher in CPFE group compared to IPF group [264.70 U/ml (228.90-786) vs 233.60 (101.8-425.4), p<0.001]. Serum KL-6 levels of 245.4 U/ml and higher have 81% sensitivity and 73% specificity for the discrimination of CPFE from IPF. Conclusions: Our study has shown that serum KL-6 level is a promising biomarker to differentiate CPFE from IPF. In CPFE cases respiratory and functional parameters are worse than those of pure fibrosis cases.Publication Approach to heart failure in the elderly(Turkish Soc Cardiology, 2017-09-01) Yeşilbursa, Dilek; YEŞİLBURSA, DİLEKThe prevalence of heart failure increases with age. Several specific changes in cardiac structure and function are associated with cardiac ageing. Because of age-associated changes leading to diastolic dysfunction, heart failure with preserved ejection fraction is the most common form of heart failure in the elderly. The diagnosis of heart failure may be difficult to diagnose in elderly patients because of a lack of typical symptoms and physical findings. The elderly patients may respond differently to heart failure medications. Age-associated changes in physiology, comorbidities, drug interaction, medication side-effects, and compliance should be considered when choosing a drug to manage heart failure in the elderly.Publication Management of hyperkalemia in heart failure(Kare Publ, 2021-10-01) Altay, Hakan; Çavuşoğlu, Yüksel; Çelik, Ahmet; Demir, Şerafettin; Kılıçarslan, Barış; Nalbantgil, Sanem; Temizhan, Ahmet; Tokgöz, Bülent; Ural, Dilek; Yıldırımtürk, Özlem; Yılmaz, Mehmet Birhan; Yeşilbursa, Dilek; YEŞİLBURSA, DİLEK; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Kardiyoloji Anabilim Dalı.Hyperkalemia is a common electrolyte abnormality in heart failure (HF) that can cause potentially life-threatening cardiac arrhythmias and sudden cardiac death. HF patients with diabetes, chronic kidney disease and older age are at higher risk of hyperkalemia. Moreover, hyperkalemia is also often associated with the use of renin-angiotensin-aldosterone system inhibitors (RAASi) including angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, mineralocorticoid receptor antagonists and sacubitril-valsartan. In clinical practice, the occurrence of hyperkalemia is a major concern among the clinicians and often limits RAASi use and/ or lead to dose reduction or discontinuation, thereby reducing their potential benefits for HF. Furthermore, recurrent hyperkalemia is frequent in the long-term and is associated with an increase in hyperkalemia-related hospitalizations. Therefore, management of hyperkalemia has a special importance in HF patients. However, treatment options in chronic management are currently limited. Dietary restriction of potassium is usually ineffective with variable adherence. Sodium polystyrene sulfonate is commonly used, but its effectiveness is uncertain and reported to be associated with intestinal toxicity. New therapeutic options such as potassium binders have been suggested as potentially beneficial agents in the management of hyperkalemia. This document discusses prevalence, predictors and management of hyperkalemia in HF, emphasizing the importance of careful patient selection for medical treatment, uptitration of the doses of RAASi, regular surveillance of potassium and treatment options of hyperkalemia.Publication Bilateral perirenal fluid accumulation associated with tetralogy of fallot(Modestum Ltd, 2017-01-01) Sağ, Saim; Nas, Ömer Fatih; Öztürk, Alper; Yeşilbursa, Dilek; Erdoğan, Cüneyt; Sağ, Saim; NAS, ÖMER FATİH; Öztürk, Alper; YEŞİLBURSA, DİLEK; Erdoğan, Cüneyt; Uludağ Üniversitesi/Tıp Fakültesi/Radyoloji Anabilim Dalı.; Uludağ Üniversitesi/Tıp Fakültesi/Kardiyoloji Anabilim Dalı.; AAG-8561-2021; AAW-9185-2020; JKP-3323-2023; EHA-0046-2022; COE-1124-2022This report describes a case of spontaneously developing bilateral perirenal fluid accumulation in a patient under monitoring for tetralogy of Fallot. The causal pathophysiology of perirenal fluid accumulation in patients with tetralogy of Fallot is unidentified. As a result of comprehensive examinations we establish that perirenal fluid develops due to high hematocrit. Perirenal fluid did not relapse after repeated phlebotomy treatment. Our case is the first to describe the combination of tetralogy of Fallot and perirenal fluid accumulation in the literature.